The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Prognostic value of proliferation in invasive breast cancer: a review: Table 1
Open accessAbstract
Breast cancer is the leading cause of death among solid tumours in women, and its incidence is increasing in the West. Adjuvant chemotherapy and hormonal treatment improve survival but have potentially serious side effects, and are costly. Because adjuvant treatment should be given to high risk patients only, and traditional prognostic factors (lymph node status, tumour size) are insufficiently accurate, better predictors of high risk and treatment response are needed. Invasive breast cancer metastasises haematogenously very early on, so many breast cancer prognosticators are directly or indirectly related to proliferation. Although studies evaluating the role of individual proliferation regulating genes have greatly increased our knowledge of this complex process, the functional end result—cells dividing—has remained the most important prognostic factor. This article reviews the prognostic value of different proliferation assays in invasive breast cancer, and concludes that increased proliferation correlates strongly with poor prognosis, irrespective of the methodology used. Mitosis counting provides the most reproducible and independent prognostic value, and Ki67/MIB1 labelling and cyclin A index are promising alternatives that need methodological fine tuning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of screening mammography. A meta-analysis
Kerlikowske, K. M. (1995) · JAMA · doi:10.1001/jama.273.2.149 · Cited by 1,131
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L.-C., Mayall, B. H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.845 · Cited by 723
Cochrane review on screening for breast cancer with mammography
Olsen, O., & Gøtzsche, P. C. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06449-2 · Cited by 710
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Ki67 protein: the immaculate deception?
Brown, D. C., & Gatter, K. C. (2002) · Histopathology · doi:10.1046/j.1365-2559.2002.01343.x · Cited by 509
Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500
Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
Marcus, J. N., Watson, P., Page, D. L., Narod, S. A., Lenoir, G. M., Tonin, P., Linder-Stephenson, L., Salerno, G., Conway, T. A., & Lynch, H. T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w · Cited by 454
Le Doussal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyratos, F., & Brunet, M. (1989) · Cancer · doi:10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g · Cited by 377
van Diest, P. J., Baak, J. P. A., Matze-Cok, P., Wisse-Brekelmans, E. C. M., van Galen, C. M., Kurver, P. H. J., Bellot, S. M., Fijnheer, J., van Gorp, L. H. M., Kwee, W. S., et al. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90313-r · Cited by 353
Self-citation
Cited by
Breast Cancer Histopathology Image Analysis: A Review
Veta, M., Pluim, J. P. W., van Diest, P. J., & Viergever, M. A. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2303852 · Cited by 696
Self-citationAssessment of algorithms for mitosis detection in breast cancer histopathology images
Veta, M., van Diest, P. J., Willems, S. M., Wang, H., Madabhushi, A., Cruz-Roa, A., Gonzalez, F., Larsen, A. B. L., Vestergaard, J. S., Dahl, A. B., et al. (2015) · Medical Image Analysis · doi:10.1016/j.media.2014.11.010 · Cited by 480
Self-citationCancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
Stuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008) · The Breast · doi:10.1016/j.breast.2008.02.002 · Cited by 431
Salvi, M., Acharya, U. R., Molinari, F., & Meiburger, K. M. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104129 · Cited by 386
Imaging of Cell Proliferation: Status and Prospects
Bading, J. R., & Shields, A. F. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046391 · Cited by 320
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Veta, M., Heng, Y. J., Stathonikos, N., Bejnordi, B. E., Beca, F., Wollmann, T., Rohr, K., Shah, M. A., Wang, D., Rousson, M., et al. (2019) · Medical Image Analysis · doi:10.1016/j.media.2019.02.012 · Cited by 315
Self-citationProliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi352 · Cited by 307
Tellez, D., Balkenhol, M., Otte-Höller, I., van de Loo, R., Vogels, R., Bult, P., Wauters, C., Vreuls, W., Mol, S., Karssemeijer, N., et al. (2018) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2018.2820199 · Cited by 288
“It is assessed by examination of hematoxylin and eosin (H&E) stained tissue sections using bright-field microscopy [3].”
MethodKenny, L., Coombes, R. C., Vigushin, D. M., Al-Nahhas, A., Shousha, S., & Aboagye, E. O. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0379-4 · Cited by 275
Deep learning in mammography and breast histology, an overview and future trends
Hamidinekoo, A., Denton, E., Rampun, A., Honnor, K., & Zwiggelaar, R. (2018) · Medical Image Analysis · doi:10.1016/j.media.2018.03.006 · Cited by 273
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0248 · Cited by 259
Dai, H., van't Veer, L., Lamb, J., He, Y. D., Mao, M., Fine, B. M., Bernards, R., van de Vijver, M., Deutsch, P., Sachs, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3953 · Cited by 257
Veta, M., van Diest, P. J., Jiwa, M., Al-Janabi, S., & Pluim, J. P. W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161286 · Cited by 127
Kim, J.-Y., Jeong, H. S., Chung, T., Kim, M., Lee, J. H., Jung, W. H., & Koo, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.17775 · Cited by 115
Sandbank, J., Bataillon, G., Nudelman, A., Krasnitsky, I., Mikulinsky, R., Bien, L., Thibault, L., Albrecht Shach, A., Sebag, G., Clark, D. P., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00496-w · Cited by 112
Regression-based Deep-Learning predicts molecular biomarkers from pathology slides
El Nahhas, O. S. M., Loeffler, C. M. L., Carrero, Z. I., van Treeck, M., Kolbinger, F. R., Hewitt, K. J., Muti, H. S., Graziani, M., Zeng, Q., Calderaro, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45589-1 · Cited by 108
NRF2 immunolocalization in human breast cancer patients as a prognostic factor
Onodera, Y., Motohashi, H., Takagi, K., Miki, Y., Shibahara, Y., Watanabe, M., Ishida, T., Hirakawa, H., Sasano, H., Yamamoto, M., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0234 · Cited by 81
Metadata
- Authors
- van Diest, P. J., van der Wall, E., & Baak, J. P. A.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2004-06-25
- Volume
- 57
- Issue
- 7
- Pages
- 675-681
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W2169160999
- Cited by
- 385
- References
- 65
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.